Marinomed Biotech AG
MARI.VI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.00 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $8.32 |
| Beta | -0.25 |
| Outstanding Shares | 1,778,333 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 0.48 |
|---|---|
| PEG | -0.04 |
| Price to Sales | 0.67 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
September 16, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
April 21, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Marinomed Biotech AG
32 employees
CEO: Andreas Grassauer
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally...